ASCO 2020：11项中国研究工作入选口头报告，17项Poster报告

不受全球另行冠非典型肺炎负面影响，原定于5月29日~6月2日在芝加哥举行的加拿大临床学就会（ASCO）年就会今年将首次以线上形式举办，这是目前最大规模的线上盛宴。今天，全体就会议的参考资料题目披露，共103个sessions，中都国共有11项研究成果入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或佩佩替尼加卡培他滨运用于HER2+冠心病前列腺结核病（PHOEBE）：一项III期随机实验。

音乐就会：冠心病前列腺结核病

编者：中都国医学科学院医务人员徐兵河研究成果员、马飞研究成果员，山东大学原为医务人员胡夕春研究成果员等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态前列腺结核病标准治疗法后卡培他滨确保节拍抗生素的III期实验（SYSUCC-001）。

音乐就会：前列腺结核病—角化/区域/辅助治疗法

编者：中都山大学传染病其中都心王树森研究成果员等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用冠心病脑的表型特征来预报消化道中都循环DNA检验的标准差: 另行工具箱对抗外公对手

音乐就会：另行工具箱解决外公问题

编者：李美芹 李昔等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肝肝细胞结核病的二线治疗法：一项对外开放标识、随机、多其中都心II/III期实验。

音乐就会：肠消化道结核病—消化道膀胱、癌变和水火

编者：湖南大学伊万基夫齐医务人员毕锋研究成果员、中都国人民解放军八一医务人员秦叔逵研究成果员等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都国早期膀胱结核病高血压阿帕替尼二线治疗法：一项随机、治疗法法印证、测试者III期研究成果

音乐就会：肠消化道结核病—消化道膀胱、癌变和水火

编者：中都国人民解放军八一医务人员秦叔逵研究成果员、湖南大学伊万基夫齐医务人员李秋研究成果员等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期发作病态卵巢结核病二次肝细胞减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

研讨：妇科结核病症

编者：山东大学原为中都山医务人员臧荣余研究成果员等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈结核病根治病态乳房手术后辅助治疗法中都的序贯放抗生素对比基本上恶病态肿瘤或不间断放抗生素（STARS研究成果）：一项随机、印证、对外开放标识的III期实验。

全体就会议：妇科结核病症

编者：中都山大学传染病其中都心凌云研究成果员、刘继红研究成果员等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比抗生素运用于可切除的EGFR等位基因的N1-N2期NSCLC-随机III期临床实验的最终总体求生存量化。

研讨：心脏病—非小肝细胞角化-区域/小肝细胞/其他颈部

编者：广东省人民医务人员吴一龙研究成果员等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因寡分散非小肝细胞心脏病高血压二线嘧啶激酶类固醇牵头或不牵头积极第二线角化恶病态肿瘤：III期对外开放标识临床随机实验（SINDAS）的中都期结果（NCT02893332）。

研讨：心脏病-非小肝细胞分散

编者：四川省人民医务人员曾铭研究成果员等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态死亡-1（PD-1）的人源化IgG4单克隆抗体牵头阿昔替尼运用于冠心病黏膜阿兹海默高血压的Ib期研究成果的总求生存期和生命体多种类型量化。

研讨：阿兹海默/溃疡症

编者：北京大学医务人员郭军、盛锡楠研究成果员等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全病态和结果：非标准CAR-T肝细胞首次化学物质实验治疗法发作/难治病态T肝细胞急病态淋巴肝细胞肺炎（r/r T-ALL）的安全病态和。全体就会议：开发设计中都的治疗法电子技术-免疫治疗法。编者：斌欣等参考资料：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期膀胱表皮肝细胞结核病高血压中都的电子技术的发展：一项随机的对外开放标识II期实验（ORIENT-2）。全体就会议：肠消化道结核病-消化道膀胱结核病、膀胱结核病和水火道结核病编者：徐建明研究成果员等参考资料：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T肝细胞对髓母肝细胞瘤的造成危害病态治疗法全体就会议：中都枢神经系统编者：代红久、孙斌、杨东、徐晖、顾晶晶、魏佳、赵旭东参考资料：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺陷高血压中都的电子技术的发展全体就会议：开发设计中都的治疗法学-免疫治疗法编者：沈琳研究成果员等参考资料：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法发作/难治病态ACUTE淋巴肝细胞肺炎/淋巴瘤的尚未有化学物质临床实验全体就会议: 开发设计病态治疗法学-免疫治疗法编者简介：张明志，板桥乡等参考资料：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 昂替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头电子技术的发展于早期实体瘤高血压的Ib期研究成果全体就会议：发展病态治疗法学--分子结构靶向药剂和生命体学编者：龚继芳，沈琳研究成果员等参考资料：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头糖类和nedaplatin治疗法发作病态或冠心病膀胱表皮肝细胞结核病（ESCC）高血压的II期研究成果。全体就会议：肠消化道结核病-消化道膀胱、癌变和水火道结核病的研究成果编者：王志强于，李玉红，王德申，王凤华，任超，谭琼 王志强于、李玉红、王德深、王凤华、任超、谭琼参考资料：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体就会议：肠消化道结核病-消化道膀胱结核病、膀胱结核病和水火管结核病的二线治疗法编者：宋艳等参考资料：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体外缘RNA分类器运用于初始活体时检验高等级结核病的唾液外体外缘RNA分类器：一项多其中都心的回顾病态研究成果全体就会议：泌尿生殖系统结核病症--结核病、睾丸结核病和结核病编者简介：Liaoyuan Li等参考资料：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 角化早期宫颈结核病并发抗生素后的辅助抗生素全体就会议: 妇科结核病症编者简介： 李珉珉等参考资料：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法肾脏髓病态结核病的差异病态：基于ALTER01031实验的量化。就会福州话：细弱编者：天津市医务人员正派研究成果员参考资料：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和岁数对安洛替尼治疗法后高血压结局的负面影响: ALTER01031的亚组量化全体就会议：细弱编者：天津市医务人员正派研究成果员参考资料：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化预报I-IIIA期非小肝细胞心脏病（NSCLC）高血压术后发作: GASTO1035和GASTO1018的结果全体就会议：心脏病-非小肝细胞角化-区域病态/小肝细胞/小肝细胞/其他胸科结核病症编者：Si-Yu Wang等参考资料：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小肝细胞心脏病（NSCLC）中都EGFR嘧啶激酶类固醇的另行型耐药系统全体就会议:心脏病-非小肝细胞冠心病心脏病编者简介：赵昕，金艾利，满宇，欧青楼，双带，薛武，杨少，范敏 赵昕、金艾利、满宇、欧青楼、双带、薛武、杨绍、范敏参考资料：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验中都早期阿兹海默总求生存的替代终点全体就会议：阿兹海默/溃疡症编者：聂润聪，袁书强于，李元芳，陈英波，周志伟 聂润聪、袁书强于、李元芳、陈英波、周志伟参考资料：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法发作或冠心病原发病态恶病态骨高血压的II期研究成果全体就会议： 肉瘤编者：唐丽娜，牛晓辉，陈赓，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、朝臣、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 进一步评论者安罗替尼在早期肉瘤高血压多线治疗法中都的安全病态和。全体就会议：肉瘤编者：姚伟涛，王家强于，张鹏，斌，杜另行辉，田志浩，牛晓颖 姚伟涛、王家强于、张鹏、王鑫、杜鑫辉、田志超、牛晓英参考资料：11526标语：414